Kolliphor Surfactants Affect Solubilization and Bioavailability of Fenofibrate. Studies of in Vitro Digestion and Absorption in Rats
- 6 March 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 12 (4) , 1062-1071
Abstract
Selection of excipients for drug formulations requires both intellectual and experimental considerations as many of the used excipients are affected by physiological factors, e.g., they may be digested by pancreatic enzymes in the gastrointestinal tract. In the present paper we have looked systematically into the differences between Kolliphor ELP, EL, and RH40 and how they affect the bioavailability of fenofibrate, through pharmacokinetic studies in rats and in vitro lipolysis studies. The study design was made as simple as possible to avoid confounding factors, for which reason the tested formulations only comprised an aqueous micellar solution of the model drug (fenofibrate) in varying concentrations (2–25% (w/v)) of the three tested surfactants. Increased concentrations of Kolliphor ELP and EL led to increased fenofibrate AUC0–24h values. For the Kolliphor RH40 formulations, an apparent fenofibrate absorption optimum was seen at 15% (w/v) surfactant, displaying both the highest AUC0–24h and Cmax. The reduced absorption of fenofibrate from the formulation containing the highest level of surfactant (25% w/v) was thought to be caused by some degree of trapping within Kolliphor RH40 micelles. In vitro, Kolliphor ELP and EL were found to be more prone to digestion than Kolliphor RH40, though not affecting the in vivo results. The highest fenofibrate bioavailability was attained from formulations with high Kolliphor ELP/EL levels (25% (w/v)), indicating that these surfactants are the better choice for solubilizing fenofibrate in order to increase the absorption upon oral administration. Due to drug dependent effects of the different types of Kolliphor, more studies are recommended in order to understand which type of Kolliphor is best suited for a given drug.Keywords
Funding Information
- Innovation Consortium Predicting Drug Absorption
This publication has 32 references indexed in Scilit:
- Strategies to Address Low Drug Solubility in Discovery and DevelopmentPharmacological Reviews, 2013
- The Solubility–Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble DrugsThe AAPS Journal, 2012
- Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymesEuropean Journal of Pharmaceutical Sciences, 2010
- Evaluation of the Impact of Surfactant Digestion on the Bioavailability of Danazol after Oral Administration of Lipidic Self-Emulsifying Formulations to DogsJournal of Pharmaceutical Sciences, 2008
- Calculated Molecular Properties and Multivariate Statistical Analysis in Absorption Prediction2003
- Dose‐dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor ELBritish Journal of Clinical Pharmacology, 2002
- Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gutCancer Chemotherapy and Pharmacology, 2001
- The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patientsBritish Journal of Cancer, 2001
- Cremophor ELEuropean Journal of Cancer, 2001
- Mechanisms of Surfactant Effects on Drug AbsorptionJournal of Pharmaceutical Sciences, 1970